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Economic Evaluation Report and Website 
This economic evaluation report measures the cost effectiveness of an opportunistic 
Chlamydia Screening in Ireland Pilot Study conducted between 2007 and 2009. 
Further information including more detail on the methods and results can be found in 
the following accompanying reports on the Health Protection Surveillance Centre 
(HPSC) website.
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Executive Summary 
Economic Evaluation 
The aim of the economic evaluation was to examine the cost effectiveness of the two 
screening models tested in the Chlamydia Screening in Ireland Pilot (CSIP) study: (a) 
Clinical Setting screening, and (b) ’Pee-in-a-pot’ periodic screening in third level 
institution/college settings. The methodological approach comprised of a dynamic 
transmission model paired with an economic model. In both analyses, screening was 
compared to a control strategy of no organised screening, that is existing care in 
Ireland. 
A public health system or provider perspective was adopted with respect to costs. The 
analysis considered the cost of screening to the health service, and the costs of 
infection and complications, not any additional costs reported by young people in 
accepting a chlamydia screening test. Health outcomes were assessed in terms of 
major outcomes (MOs) averted and quality adjusted life years (QALYs) gained. 
The costs of Clinical Setting screening were presented in terms of the cost per offer 
(€26), the cost per negative case (€66), the cost per positive case (€152), and the cost 
per partner notified and treated (€74).  The costs of ’Pee-in-a-pot’ screening were 
presented in terms of the cost per negative case (€39), the cost per positive case 
(€125), and the cost per partner notified and treated (€74).  
In both analyses, screening was estimated to result in fewer major outcomes, fewer 
QALYs lost, and higher healthcare costs compared to the control strategy. The 
incremental cost effectiveness analyses indicated that screening in the Clinical Setting 
would result in an incremental cost per MO averted of €6,093 and an incremental cost 
per QALY gained of €94,717. ’Pee-in-a-pot’ screening was estimated to result in 
incremental cost effectiveness ratios of €2,294 per MO averted and €34,486 per 
QALY gained respectively. 
In Ireland, there is no fixed and generally agreed cost effectiveness threshold below 
which health care technologies would be considered by policy makers to be cost-
effective. Nonetheless, on the basis of other technologies that are currently funded, it 
is not likely that screening delivered in the Clinical Setting, given an incremental cost 
per QALY in the region of the €94,717 found in this study, would be considered cost 
effective.  
’Pee-in-a-pot’ screening in third level institution/college settings may be considered 
cost effective if a cost effectiveness threshold in the region of €45,000 per QALY 
gained is used. This is open to question, however, given the current economic climate 
and its resulting impact in terms of imposing further constraints on future healthcare 
budgets. It is also important to note that this strategy would have minimal in impact in 
reducing overall chlamydia prevalence in the population, if not supported by general 
population screening and prevention strategy. 
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1. Introduction 
The purpose of economic evaluation is to evaluate the cost effectiveness of health care 
technologies and to provide advice to decision makers charged with the allocation of 
health care resources. It involves a set of techniques for the systematic appraisal of 
alternative health care interventions in order to identify those strategies which provide 
the most efficient use of resources. In this study, we undertake an economic 
evaluation to explore the cost effectiveness of two models of opportunistic screening 
piloted in the Chlamydia Screening in Ireland Pilot (CSIP) study: (a) Clinical Setting 
screening, and (b) ’Pee-in-a-pot’ screening.  
2. Methodology 
The process of economic evaluation involves the comparative analysis of alternative 
courses of action in terms of their costs and consequences [1]. The methodological 
approach adopted in this analysis comprised of a dynamic transmission model paired 
with an economic model. In the base-case analyses, screening was modelled to 
represent the opportunistic screening approaches tested in the pilot study. In both 
cases, screening was compared to a control strategy of no organised screening, or in 
other words existing care in Ireland. The methodological process consisted of three 
phases of analysis: (1) cost analysis; (2) modelling analysis, and (3) incremental cost 
effectiveness analysis. Each stage of analysis is described in the following paragraphs. 
2.1 Cost Analysis 
The purpose of the cost analysis was to estimate the healthcare resource implications 
associated with implementing the opportunistic screening programmes in the pilot 
study. Consistent with HIQA guidelines [2] a publicly funded health system 
perspective was adopted in that costs falling outside the publicly funded healthcare 
system, including costs to patients such as direct payment to general practitioners 
(GPs) when attending due to an unrelated medical complaint, travel and time off 
work, were excluded from the analysis.  
Resource items were identified and measured using resource-use record forms, 
healthcare provider questionnaires, interviews with research staff, and directly from 
the study financial accounts. A resource-use form completed by healthcare providers 
was used to prospectively record the time input requirements for each patient episode 
at various stages of the screening process. A healthcare provider questionnaire was 
conducted to identify setting specific resource use for the participating providers. 
Interviews with research staff and a detailed review of the study accounts provided 
further information on the resources required to implement the screening programmes 
and the overhead costs involved.  
Specific resource items included in the cost analysis were overheads, provider, 
support staff and volunteer time input, information leaflets, screening materials and 
consumables, laboratory materials and testing, antibiotic medications, referrals, and 
telephone, fax, and postage charges. Overheads included the costs of project 
management and coordination by the Research Health Adviser, stationary, computer 
equipment, advertising, printing, photocopying and packaging, charges, and travel 
expenses. 
2 
Resource use data collected alongside the pilot study were combined with Irish unit 
cost data to complete the cost analysis. Unit costs were obtained from national data 
sources and were transformed to Euros (€) in 2008 prices using an appropriate 
inflation rate index [3]. For further details on specific screening resource items and 
unit costs see Appendix B.1. 
The results from the cost analysis were calculated for each screening programme and 
for each stage of the screening process. The results for Clinical Setting screening were 
presented in terms of the average cost per offer, the average cost per negative case, 
the average cost per positive case, and the average cost per partner notified and 
treated. The results for ’Pee-in-a-pot’ screening were presented in terms of the 
average cost per negative case, the average cost per positive case, and the average 
cost per partner notified and treated.  
The divergence in the costing process for Clinical Setting screening and ’Pee-in-a-pot’ 
screening derives from how screening was offered in each case. Whereas screening 
was offered by a clinician in the former, this was not the case in the latter. The cost 
estimates for each programme were incorporated as input parameters in the modelling 
analysis, described in the following section, to undertake the economic evaluation. 
2.2 Modelling Analysis  
The modelling analysis was undertaken to facilitate the estimation of the cost 
effectiveness of screening and comprised of a dynamic transmission model paired 
with an economic model. The modelling component was required due to two broad 
factors which make predicting the impact and cost of chlamydia screening 
programmes difficult: 1) as chlamydia is an infectious disease there are benefits to 
reducing population prevalence beyond that of the individual, and 2) as chlamydia is 
highly transmissible via sexual contact treatment does not produce lasting immunity 
as it does not eradicate the risk of future infection. As a result, modelling frameworks 
which explicitly allow for the possibility of infection, transmission to partners, and re-
infection are required for the evaluation of chlamydia screening programmes [4]. 
A dynamic model of sexual partner change and chlamydia transmission that not only 
incorporates the identification and treatment of the individual but also partner 
notification and treatment was used for the analysis. The dynamic model by Turner et 
al [5] and the economic model by Adams et al [6], which were applied in an economic 
evaluation of opportunistic chlamydia screening in England, were adopted for the 
analysis. For the current study, the approach of Turner et al [5] and Adams et al [6] 
was adapted to reflect the Irish healthcare setting.  
A number of alternative models of chlamydia transmission have been published, each 
of which differ with respect to the underlying dynamics and assumptions regarding 
sexual behaviour and transmission parameters. Kretzschmar et al [4], in a study 
comparing three alternative modelling approaches, found that predictions from the 
alternative models may result in inconsistent policy recommendations about the likely 
effectiveness of a screening programme. Kretzschmar et al [4] were unable to identify 
a superior model because of uncertainty about a large number of key parameters and 
the lack of data for external comparison.  
Of the three approaches considered, the model by Turner et al [5] was the most 
optimistic in terms of its predicted reduction in prevalence resulting from the 
implementation of screening. This is attributed in part to the relatively low level of 
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pre-screening treatment of chlamydia assumed in this model compared to the 
alternatives. Given the uncertainty surrounding the superiority of the alternative 
modelling approaches, the current approach was adopted with the caveat that adopting 
the alternative approaches would result in more pessimistic predictions of the 
effectiveness of screening in reducing chlamydia prevalence levels.      
To summarise, the dynamic model simulates several processes. The sexual contact 
network provides the framework within which chlamydia transmission occurs. Sexual 
partnerships form and break according to behavioural algorithms, which adjust 
according to an individual’s age. Chlamydia is introduced into the population and is 
transmitted through current sexual contacts. Individuals can recover spontaneously or 
through seeking treatment, partner notification or screening. Since individuals and 
their partnerships are explicitly represented, partner notification and treatment 
(including of previous partners) can be modelled and infection status and screening 
histories recorded.  
The dynamic model was parameterised such that the sexual behaviour and chlamydia 
prevalence was representative of that in England [7, 8, 9, 10]. For the current analysis, 
the original model settings for sexual behaviour and prevalence were used and 
assumed to be transferable to Ireland. For further details on specific input parameters 
see Appendix A. While sexual attitudes and culture in Ireland may once have been 
different to other western European countries, more recently they have converged 
towards those of the United Kingdom and continental Europe [11] and clinical case 
management is similar to that of the UK. Therefore it was considered appropriate to 
use the English model for the Irish setting. 
The dynamic model simulates a hypothetical, heterosexual population of 20,000 men 
and 20,000 women aged 16 to 45 years and estimates the annual number of acute 
cases of chlamydia infection (asymptomatic and symptomatic) and the number of 
complications resulting from untreated infection for the simulated population.  
The complications modelled include pelvic inflammatory disease (PID), ectopic 
pregnancy, and tubal factor infertility in women, neonatal conjunctivitis and 
pneumonia, and epididymitis in men (see Figure 1 and Table 1). This represents a 
simplification of the true natural history which is not well understood. Only 
symptomatic PID is modelled as the probability of further complications is directly 
related to symptom severity. Furthermore, there is conflicting evidence about the 
proportion of chlamydia cases that result in PID [12, 13, 14] and about the proportion 
of PID cases that can be prevented by the detection and treatment of chlamydia [15].  
Therefore, a probability of 10% was adopted in the base-case analysis and 
probabilities of 1% and 30% were tested in sensitivity analyses to reflect the range of 
data presented in the literature. It is assumed that PID can lead to ectopic pregnancy 
and tubal factor infertility, and if a woman gives birth she can transmit infection to her 
infant causing neonatal conjunctivitis and pneumonia. 
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Figure 1. The flow of complications in women with PID and neonates exposed to 
infected others 
  
(Source: Adams et al [6]) 
Table 1. Probabilities for developing complications following acute chlamydial 
infection 
Complication Probability Value Probability applied to: 
Symptomatic PID (women) 1%,  10%, 30% Asymptomatic chlamydia 
infection 
Ectopic pregnancy (women) 7.6% Symptomatic PID 
Tubal factor infertility (women) 10.8% Symptomatic PID (excluding 
those with EP) 
Neonatal conjunctivitis  14.8% Infected women giving birth 
vaginally  
Neonatal pneumonia 7.0% Infected women giving birth 
vaginally 
Epididymitis (men) 2% Asymptomatic chlamydial 
infection 
(Source: Adams et al [6]) 
The output from the dynamic model is used in the economic model to estimate the 
health service costs and health outcomes associated with the predicted infections and 
complications. As the dynamic model is stochastic and each realisation of the model 
yields distinct estimates, an average of 40 realisations was inputted into the economic 
model. The existing economic model was adapted by incorporating Irish unit cost data 
so to make it appropriate for the analysis of screening programmes delivered in the 
Irish healthcare system. 
The modelling framework allows for the incremental analysis to be undertaken 
whereby alternative screening strategies are evaluated in terms of their relative impact 
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on the estimated number of infections and complications, the number of people 
screened and treated, and health outcomes and costs which result. The model is run 
for a time horizon of 10 years to observe the impact of screening on longer term 
complications, with all future costs and health outcomes discounted at an annual rate 
of 3.5%, an appropriate rate for health technology assessment in Ireland.  
Two screening scenarios were modelled to represent both screening approaches tested 
in the pilot study: (a) Clinical Setting screening; (b) ‘Pee-in-a-pot’ screening. In both 
cases, the screening scenario was compared to a control strategy of no organised 
screening, or in other words existing care in Ireland.  
2.2.1 Clinical Setting Screening  
In the pilot, individuals aged 18 to 29 years old who accessed one of three clinical 
settings – general practices, family planning and student health clinics - were invited 
to participate in the study. Those who agreed were offered a screen.  
Men who agreed to participate were asked to provide a urine sample and women 
either urine or cervical swab. In general practice, both general practitioners and 
practice nurses offered screening while in family planning and student health clinics 
offers were made by nurses.  
Urine or endocervical swab samples were tested for each participant by the virology 
laboratory at a local hospital. Specimens were batch tested with Polymerase Chain 
Reaction testing technology. The test used was the COBAS
® 
TaqMan
® 
CT Test v2.0 
manufactured by Roche Diagnostics, Switzerland.  
All individuals were notified of their test results by the healthcare provider and those 
with positive results were invited to attend a consultation where they received 
treatment (with Azithromycin or Doxycycline), information and counselling from a 
GP. Individuals with positive results were recalled for retesting at three to six months 
after treatment when the testing process was repeated.  
Notification of partners was undertaken by the patient, the healthcare provider or the 
Research Health Advisor who worked exclusively on the pilot study. Partner 
treatment and testing took place in general practice, family planning, student health 
and genitourinary medicine clinics. 
In the economic evaluation, screening in the clinical setting was modelled as a 
continuous process to reflect the programme delivered in the pilot study, 
incorporating a range of data on clinical setting attendance, provision of screen offer, 
participation, treatment, resource-use and cost (see Table 2).  
In the base-case analysis it was assumed that 80% of women and 50% of men 
attended a health care setting in a given year. This is based on data from a national 
population survey for representative sample of 18-29 year olds in Ireland [16]. Of 
those who attended, it was assumed for the model that 70% were offered a screen by 
the resident healthcare provider. This estimate is based on the findings from a 
systematic review of opportunistic screening strategies internationally [17]. This 
figure is higher than that which was observed in the pilot study but alternative offer 
rates, including those observed in the study, were examined in sensitivity analysis.  
It was assumed for the model that 85% of females and 64% of males accepted the 
screen offer, based on rates observed in a sample of pilot study practices. An effective 
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partner notification and treatment rate of 20% was assumed based on rates used 
elsewhere [6].  
Finally, we assume for the model that once an individual is screened they will not be 
offered screening for 1 year. While an individual may request a test within the same 
year that a screen has been offered, it is unlikely that a provider would be reimbursed 
or choose to offer repeated screens within the same calendar year to those who had 
declined a screen or been screened negative.  
The base-case assumptions result in a screening coverage rate, that is the overall 
fraction of the target population who are screened, of 48% for females and 22% for 
males. A series of one-way sensitivity analysis was undertaken to explore the impact 
of varying the assumptions of the base-case analysis (See Table 2). 
Table 2 Clinical Setting Analysis Input Parameters for Base-case and Sensitivity 
Analyses 
Input Parameter Base-Case  Analysis Sensitivity Analysis 
Male Attendance Rate 50% n/a 
Female Attendance Rate 80% n/a 
Healthcare Provider Offer Rate 70% 5%, 20%, 40%, 100% 
Male Acceptance Rate 64% 50%, 85% 
Female Acceptance Rate 85% 50%, 64% 
Effective Partner Notification and 
Treatment 
20% 40% 
Screen frequency 1 per year (365 days 
minimum between 
screens) 
No minimum time between 
screens 
2.2.2 ‘Pee-in-a-pot’ Screening  
In the pilot ‘Pee-in-a-pot’ programme, males and females aged 18 to 29 years old 
attending two third level institution/college settings in Galway city were 
opportunistically targeted for screening over a period of one week. 
A marketing and promotional campaign was conducted in each setting by the 
Research Health Advisor, supported by a team of student volunteers who were paid a 
daily reimbursement rate, to inform the target population about the screening 
programme.  
Informational materials and specimen sample packs, which included a test sample 
container and an anonymised contact form to record a mobile telephone number for 
the purposes of communicating the test result, were made freely available at various 
locations on campus in both settings.  
Participants returned completed specimens and contact forms to unmanned, sealed 
collection points. Urine samples were collected and sent for testing at the virology 
laboratory at a local hospital. Specimens were batch tested with Polymerase Chain 
Reaction testing technology. The test used was the COBAS
® 
TaqMan
® 
CT Test v2.0 
manufactured by Roche Diagnostics, Switzerland.  
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All individuals were notified of their test results by text message and those with 
positive results were invited to attend a consultation where they received treatment 
(with Azithromycin or Doxycycline), information and counselling from a GP. 
Individuals with positive results were recalled for retesting at three to six months after 
treatment when the testing process was repeated.  
Notification of partners of positive cases was undertaken by the patient, the healthcare 
provider or the Research Health Advisor, depending on the patient’s preference. 
Partner treatment and testing took place in general practice, family planning, student 
health and genitourinary medicine clinics. 
In the economic evaluation, screening was modelled as a pulse process to reflect a 
once-off, annual, week-long programme as delivered in the pilot study. 
The combined student population in the two participating third level institutions 
consisted of 6,977 males and 11,076 females. Assuming all these individuals fall 
within the target population (aged 18-29 years), the student population comprised 
25% of the total male target population (29,737 males) and 38% of the total target 
female population (29,060 females) in the Galway city and county region.  
These data were incorporated as the eligible screening population in the modelling 
analysis. In addition, data from the Irish College Lifestyle and Attitudinal National 
Survey [18] were used to further classify the eligible population into the respective 
age profile categories attending third level institutions.  
Over the course of the week-long pilot study, 1249 screening kits/packs were made 
available to the student population. As a result, 7% of the student population were 
eligible to participate in the screening programme (Denominator: combined 
(6,977+11,076) student population; Numerator: 1249 kits/packs distributed). A 
screening uptake rate of 47%, estimated based on the uptake rate of the screening 
kits/packs in the pilot study, was assumed for both males and females (Denominator: 
1249 kits/packs distributed; Numerator: 592 kits/packs returned/used).  
In addition, a range of data on process, resource use and cost were collected for the 
participating student health clinics and incorporated in the analysis.  
2.3 Incremental Cost Effectiveness Analysis 
An incremental analysis was undertaken to explore the cost effectiveness of both 
opportunistic screening strategies relative to no organised screening, that is, current 
practice. This involved comparing the alternative strategies in terms of both their costs 
and effectiveness and applying a set of decision rules which define one treatment 
option as cost effective relative to a comparator. In addition, uncertainty in the 
analysis was explored using sensitivity analysis. Each stage in this process in detailed 
in the following paragraphs. 
2.3.1 Costs 
A public health system perspective was adopted with respect to costs, with two broad 
components of healthcare cost included in the analysis: the costs of screening, and the 
costs of infections and complications. As described above, the costs of screening were 
estimated prospectively alongside the pilot study (for further details on specific 
resource items and unit costs see Appendix B.1). 
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The average cost per complication arising from undiagnosed infection was estimated 
using a range of resource utilisation and unit cost data. As data on the resource 
utilisation associated with the treatment of symptomatic infection and chlamydial 
complications were not collected alongside the pilot study, this information was 
obtained retrospectively from a variety of national data sources and, where necessary, 
published UK data sources.  
In particular, the treatment process for chlamydial complications was informed by the 
treatment protocols adopted in the study by Adams et al [6] when evidence for Ireland 
was unavailable. The adopted treatment protocols were reviewed by the study 
clinicians to ensure that they were applicable to the Irish healthcare setting. In all 
cases, resource utilisation for diagnosis, testing, treatment, and healthcare setting 
attendance (primary care and secondary care) were combined with Irish unit cost data 
to estimate the average costs of care (for further details on specific resource items and 
unit costs see Appendix B.3).  
Unit costs were obtained from national data sources and were transformed to Euros 
(€) in 2008 prices using an appropriate inflation index [3]. The average costs per 
complication are presented in Table 3.  
2.3.2 Effectiveness 
Two measures of health outcome were considered in the effectiveness analysis: the 
number of major outcomes (MOs) averted and quality adjusted life years (QALYs) 
gained. MOs comprised of the complications which were predicted to arise from 
untreated infection and included cases of PID, ectopic pregnancy, tubal factor 
infertility, neonatal conjunctivitis, neonatal pneumonia and epididymitis.  
The QALY losses associated with chlamydial complications were estimated by 
multiplying a utility valuation for each condition by the duration spent in that 
particular health state. Estimates of utility weights were taken from studies by the 
Institute of Medicine [19] and Smith et al [20], and the duration periods were assumed 
to be the same as in Adams et al [6]. The average QALY loss per acute complication 
is presented in Table 3 (for further details see Appendix C). 
Table 3. Chlamydial Complications: Cost and QALY Loss Impacts 
Infections and Complications Cost (€) QALY Loss 
Pelvic inflammatory disease (PID) 328.88 0.008 
Ectopic pregnancy 3,935.07 0.010 
Tubal factor infertility 1,182.00 0.871 
Epididymitis 450.32 0.011 
Neonatal conjunctivitis 88.04 0.001 
Neonatal pneumonia 876.29 0.037 
Note: See Appendix C for further details 
2.3.3 Decision Rules 
The economic evaluation framework requires a set of decision rules which define a 
health care technology as cost effective relative to a comparator [1]. These include if:  
(a) It is less costly and more effective;  
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(b) It is more costly and more effective, but its additional cost per additional unit 
 of effect is considered worth paying by decision makers; and  
(c) It is less costly and less effective, but the additional cost per additional unit of 
 effect generated by the comparator is not considered worth paying by 
 decision makers.   
In scenario (a), the outcome in straightforward, that is, the less costly and more 
effective comparator is dominant. In scenarios (b) and (c), a key factor in the 
determination of cost effectiveness is the threshold value or ceiling ratio, which is 
interpreted as the decision maker’s maximum willingness to pay for an additional unit 
of health gain. In such cases, the results from economic evaluation are presented in 
terms of an incremental cost effectiveness ratio or ICER (Difference in Mean 
Cost/Difference in Mean Effect) which is compared directly to the appropriate 
threshold value. The results from economic evaluation should enable the identification 
of the decision rule scenario which applies for a given comparative analysis. 
In Ireland, there is no fixed and generally agreed cost effectiveness threshold below 
which health care technologies would be considered by policy makers to be cost 
effective [2]. However, in the current economic climate it is likely to be somewhat 
less than the €45,000 per QALY gained that has previously been mooted in the 
literature. Indeed, it is now likely that only those interventions with an incremental 
cost effectiveness ratio of €20,000 per QALY gained or less will have any likelihood 
of being considered cost effective.  
Given the uncertainty relating to the appropriate cost effectiveness threshold value 
and the underlying assumptions of the modelling approaches adopted, a series of 
sensitivity analyses was undertaken to explore the robustness of the cost effectiveness 
results across alternative threshold values and to variations in the modelling 
assumptions adopted for the base-case analyses.  
2.3.3 Sensitivity Analysis 
To explore the uncertainty in the analysis a range of sensitivity analyses were 
undertaken.  
First, a probabilistic sensitivity analysis was used to translate the uncertainty in 
individual input parameters into a measure of uncertainty in the overall cost 
effectiveness results [21]. Clinical, resource and cost input parameters in the model 
were assigned probability distributions (see Appendix A for further details), and for 
each of the 40 stochastic realisations of the dynamic model, the model results were re-
estimated 500 times drawing randomly from that distribution. The probabilistic results 
were used to construct cost effectiveness acceptability curves, which estimate the 
probability of the screening programme being cost effective for a range of potential 
cost effectiveness threshold values per additional QALY gained [22].  
Second, a series of one-way sensitivity analyses were undertaken to examine the 
impact of varying the assumptions of the base-case analyses on the cost effectiveness 
results (as detailed in Tables 1 and 2).  
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3. Results 
The results from each stage of the economic evaluation are presented in the following 
sections. 
3.1 Cost Analysis Results 
The costs of screening were estimated prospectively alongside the pilot study and are 
presented in Table 4. The results from the cost analysis were calculated individually 
for each screening programme and for each stage of the screening process.  
The results for the Clinical Setting screening programme are presented in terms of the 
average cost per offer (€26), the average cost per negative case (€66), the average 
cost per positive case (€152), and the average cost per partner notified and treated 
(€74).  
In the base-case analysis, it was assumed that GPs and practice nurses equally shared 
the work of offering screens in general practice. Given the cost differential between 
GP and nurse led care, cost results for scenarios in which GPs and nurses offered the 
screen alone were estimated as part of the sensitivity analysis. 
The results for the ‘Pee-in-a-pot’ screening programme are presented in terms of the 
average cost per negative case (€39), the average cost per positive case (€125), and 
the average cost per partner notified and treated (€74).  
Table 4. Cost Analysis Results 
Screening Programme Clinical  
Setting 
Base-Case 
€ 
Clinical 
Setting 
GP Only 
€ 
Clinical 
Setting 
PN Only 
€ 
Non-Clinical 
Setting 
‘Pee-in-a-pot’ 
€ 
Cost per Offer  
(no screening uptake) 
26 38 15 n/a 
Cost per Negative Case 66 91 42 39 
Cost per Positive Case 152 177 128 125 
Cost per Partner Notified 
and Treated 
74 74 74 74 
(Euros (€) in 2008 prices) GP – general practitioner; PN – practice nurse 
3.2 Incremental Cost Effectiveness Results 
The results from the cost analysis were combined with a range of additional clinical, 
utility, resource use and cost data within the modelling framework to complete the 
economic evaluation of the proposed screening strategies.  
Prior to screening implementation, the steady state prevalence levels projected by the 
dynamic model ranged from 2.5% to 3.5%. Highest levels were observed in the 
youngest age groups reflecting their higher turnover of partners compared with older 
ages (see Figure 2).  
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Figure 2. Pre-screening age-specific prevalence: the equilibrium (steady-state) 
prevalence by males and females by age groups 
 
Prevalence data from the UK [7, 8, 9, 10] were used to parameterize the model. The 
decision to adopt UK data was pragmatic in nature and was informed by the limited 
availability of prevalence data for an Irish population, and in particular for those aged 
18 years old and younger.   
The modelled screening scenarios were then entered into the model and evaluated in 
terms of their impact on projected prevalence, the resulting numbers of infections and 
complications, and the health outcomes and costs associated. The findings from the 
incremental analyses which compared each modelled scenario to the control of no 
organised screening are detailed in Table 5 and in the following sections. 
3.2.1 Clinical Setting Screening: Base-case Results 
The results for the analysis of opportunistic screening delivered in the Clinical Setting 
indicate that screening led to improved health outcomes but required additional health 
care resources even when programme outlays were set against projected savings from 
avoided infections and complications.  
Within the modelled population of 20,000 males and 20,000 females males aged 16 to 
45 years, the annual number of screens in the target population of 18 to 29 year olds 
was 1,960 in men and 4,128 in women. The impact of screening was a fall in the 
projected prevalence level, as depicted in Figure 3, and an improvement in population 
health through reductions in the number of MOs experienced and the number of 
QALYs lost.    
The incremental results indicate that screening, when compared to control, was 
associated with 699 MOs averted and 45 QALYs gained at an additional cost of 
€4,258,868 over a 10 year period. Discounting future costs and effects to the base 
year, this translated into an incremental cost per MOA of €6,093 and an incremental 
cost per QALY gained of €94,717.  
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While no single cost effectiveness threshold for health technology assessment is in 
operation in Ireland, the cost effectiveness acceptability curve in Figure 4 indicates 
that the probability of screening being cost effective is less than 1% for a range of 
potential threshold values of up to and including €45,000 per QALY gained. This 
would suggest that Clinical Setting screening, as modelled in the analysis, is unlikely 
to be considered cost effective. 
Figure 3. Prevalence Pre and Post Screening Implementation – Clinical Setting 
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Figure 4. Cost Effectiveness Acceptability Curve – Clinical Setting Screening 
 
3.2.2 Clinical Setting Screening: One-Way Sensitivity Analysis 
Results 
A series of one-way sensitivity analyses were undertaken to explore the impact of 
varying the assumptions of the base-case analysis. The results are presented in Table 5 
and were broadly similar to those observed in the base-case analysis, in that screening 
was predicted to result in fewer major outcomes, fewer QALYs lost, and higher 
healthcare costs than the control strategy. The sensitivity analysis undertaken included 
the following:  
 PID Progression Rate: 10%, 30% 
 Nurse Led Screening Programme 
 GP Led Screening Programme 
 Student Health Clinic Screening Programme 
 Family Planning Screening Programme 
 No minimum Gap Between Screens 
 Provider Offer Rate: 5%, 20%, 40%, 100% 
 Patient Acceptance Rate: 50%, 64%, 80% 
 Partner Notification Rate: 40% 
 Discount Rate: 0%, 6% 
The PID progression rate was shown to be a significant parameter in the cost 
effectiveness analysis. Increasing the rate from 10% to 30% had the effect of reducing 
the incremental cost per QALY gained to €39,126. However, recent evidence calls 
into question the likelihood of chlamydia progression to PID being as high as 30% 
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[15]. Conversely, reducing the PID progression rate to 1% increased the ICER to 
€700,144 per QALY gained.  
Nurse led screening (one in which only the nurse offered testing to eligible 
individuals) was shown to be a less costly strategy than GP led screening. However 
neither strategy is likely to be considered cost effective, yielding incremental cost per 
QALY ratios of €62,603 and €113,523 respectively. 
Screening offered individually in student health and family planning clinics yielded 
ICERs of €46,618 and €39,185 per QALY gained respectively. While these results are 
more cost effective than those reported for the clinical settings combined, they are 
subject to a number of caveats. Firstly, data on screening coverage for both family 
planning and student health settings were only obtained for the limited number of 
these clinics which participated in the pilot study. Evidence from a larger range and 
number of settings would be required to substantiate the robustness of these results.  
Secondly, screening in these settings has lower coverage in the target population than 
the base-case strategy and are less effective in identifying infection and reducing 
overall prevalence levels. This has direct implications for the cost effectiveness 
analysis as the total cost of implementing screening is less for programmes with low 
coverage than programmes with high coverage.  
In addition, the cost of identifying a positive case in the years after screening 
implementation is less in a low coverage programme. This is because the impact of 
screening in reducing chlamydia prevalence is less in a low coverage programme, 
which means that there are more residual cases in the target population, which can be 
detected at a lower cost per case than would be the case if the programme had high 
coverage. Consideration must be also given to equity concerns arising from offering 
screening in a manner that potentially excludes members of the target population who 
do not attend third level institutions or family planning clinics.   
In the base-case analysis, we assume that once an individual is screened they are 
ineligible for an opportunistic screening offer for 1 year. An alternative approach is to 
assume that individuals are eligible for a screening offer each time they attend the 
clinical setting. Eliminating the assumption of a minimum gap between screens has 
the result of increasing the ICER to €129,303.  
Altering the healthcare provider offer rate to 5%, 20% and 40% to reflect the rates 
observed in the pilot study did have the impact of reducing the ICER to €69,991, 
€74,045, and €87,132 respectively. Alternatively, increasing the offer rate to 100% 
had the impact of increasing the ICER to €97,733. This can be attributed to the 
positive relationship between the offer rate and the coverage rate of the screening 
programme, and the resulting impacts on the total cost of screening implementation. 
The remaining one-way sensitivity analyses, which varied the acceptance, effective 
partner notification and discount rates, did not show significant impacts in terms of 
improving the likely cost effectiveness of screening (see Table 5). 
3.2.3 ‘Pee-in-a-pot’ Screening Results 
The results for the analysis of opportunistic ‘Pee-in-a-pot’ screening offered in non-
clinical third level institution/college settings also indicate that screening led to 
improved health outcomes but required additional health care expenditures relative to 
control. 
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Within the modelled population of 20,000 males and 20,000 females males aged 16 to 
45 years, screening led to a fall in the projected prevalence level, as depicted in Figure 
5, leading to an improvement in population health through reductions in the number 
of MOs experienced and the number of QALYs lost.    
The incremental results indicate that screening, when compared to control, was 
associated with 44 MOs averted and 3 QALYs gained at an additional cost of 
€100,513 over 10 years. Discounting future costs and effects to the base year, this 
translated into an incremental cost per MOA of €2,294 and an incremental cost per 
QALY gained of €34,486.  
The cost effectiveness acceptability curve in Figure 6 indicates that for the potential 
cost effectiveness threshold values of €15,000, €30,000 and €45,000, the probability 
of the screening being cost effective is 14%, 41% and 94% respectively.  
This would suggest that the ‘Pee-in-a-pot’ screening programme may be considered 
cost effective if a cost effectiveness threshold in the region of €45,000 per QALY 
gained is in operation. This is open to debate as the likely threshold value of a public 
health system will be a function of its budget constraint, which in turn is influenced 
by the broader economic environment. The implication being that decision makers in 
Ireland may not be willing or able to pay as much in the future as was the case in 
years gone by. 
Figure 5. Prevalence Pre and Post Screening Implementation – ‘Pee-in-a-pot’ 
Screening 
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Figure 6. Cost Effectiveness Acceptability Curve - ‘Pee-in-a-pot’ Screening 
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4. Discussion 
In conclusion, we examined the costs and cost effectiveness of opportunistic 
chlamydia screening delivered in clinical and non-clinical settings in Ireland, as 
proposed in the Chlamydia Screening in Ireland Pilot (CSIP) study. The consideration 
of alternative screening models was beyond the remit of the study. 
The results indicate that the Clinical Screening strategy, as modelled, could reduce 
prevalence and improve population health, if sufficient coverage was achieved in the 
likely target population, which would be dependent on provider offer rates and patient 
/ client acceptance rates (see 2.2).  However, this would be expensive, and is unlikely 
to be considered cost effective given current budget constraints in Ireland.  
The results from the ‘Pee-in-a-pot’ strategy, as modelled, may be considered cost 
effective if decision makers are willing to pay a threshold in the region of €45,000 per 
QALY gained. However, whereas this might have merited serious consideration when 
the pilot study was first commissioned in late 2006, this option would be subject to 
much more stringent consideration given current economic conditions in Ireland. 
Indeed, it is now likely that only those interventions with an incremental cost 
effectiveness ratio of €20,000 per QALY gained or less will have any likelihood of 
being considered cost effective. Furthermore, it is evident that ‘Pee-in-a-pot’ 
screening would have a low level of coverage in the target population and, as a result, 
a minimal effect in terms of reducing overall prevalence levels and improving 
population health.  
The process of offering screening solely in third level institution/college settings also 
gives rise to important equity concerns as members of the target population who do 
not attend such institutions would be excluded from screening. Therefore, the 
potential for adopting the ‘Pee-in-a-pot’ strategy to settings frequented by more 
disadvantaged young people would need to be explored. 
The results from the sensitivity analyses generally confirm those from the base-case 
Clinical Setting analysis. Most notably, an increased probability of 30% for chlamydia 
infection progressing to PID had the effect of reducing the incremental cost per 
QALY gained to €39,126. However, recent evidence from a study by Oakeshott et al 
[15] suggests that this may significantly overestimate the true probability value and 
estimated rates of progression to PID between 10% and 1% (with ICERs €94,717 and 
€700,144 respectively) may be more appropriate.   
Eliminating the minimum gap of one year between screenings had the result of 
increasing the ICER, indicating that increasing the annual rate of screening does not 
improve cost effectiveness. Lowering the healthcare provider offer rate had the impact 
of reducing the ICER while increasing the offer rate increased the ICER. This reflects 
the positive relationship between the offer rate, the coverage rate, and the total costs 
of screening implementation, and conversely the negative relationship between total 
costs and cost effectiveness.  
Practice nurse led screening was shown to be a less costly strategy than GP led 
screening; however neither strategy is likely to be considered cost effective. As was 
the case in the other sensitivity analyses, which varied offer, acceptance, effective 
partner notification, and discount rates, there was little evidence to suggest that the 
proposed Clinical Setting strategy is likely to be considered cost effective by policy 
makers in Ireland. 
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The findings from our analysis of Clinical Setting screening can be directly compared 
to those from the study by Adams et al [6] which applied the same modelling 
approach to examine the cost effectiveness of opportunistic screening in clinical 
settings in England. That study reported that offering an annual screening test to men 
and women aged less than 20 years may be cost effective. Moreover, the ICER for an 
equivalent screening scenario to that modelled in our study was €54,000 per QALY 
gained, suggesting that it is also unlikely to be deemed cost effective.  
Notably, the results from our cost analysis indicated that cost estimates for screening 
and for the treatment of complications were appreciably higher in Ireland than in the 
earlier English study. In addition, the cost estimates reported here are higher than 
those reported in more recent English study examining the costs of different strategies 
for chlamydia screening and partner notification by Turner et al [23]. The divergence 
in costs across the two countries may be attributed to a range of factors including 
actual differences in the unit costs of healthcare as well as differences in how 
healthcare services are financed.  
These results can also be compared to those from other studies which, using 
alternative dynamic modeling frameworks, reported conflicting results for the cost 
effectiveness of chlamydia screening strategies in various countries. Anderson et al 
[24], Gift et al [25], Welte et al
 
[26] and deVries et al [27] individually found that 
various forms of opportunistic and proactive screening were cost effective in 
Denmark, the Unites States and the Netherlands respectively. Conversely, Roberts et 
al
 
[28] found that proactive register based screening in the United Kingdom was not 
cost effective.  
Notwithstanding the differences in the screening strategies evaluated, the healthcare 
systems involved, and the costing methods adopted, the divergence in results across 
the reported studies is likely in part to reflect key differences in the underlying 
dynamics and assumptions in the models adopted [4]. For example, as in the study by 
Roberts et al
 
[28], we adopted a conservative estimate of 10% with respect to PID 
progression. This is in contrast to the studies by Anderson et al [24], Gift et al [25], 
Welte et al
 
[26] and deVries et al [27], which adopted equivalent probabilities of 25%, 
20%, 20% and 15% respectively. As noted, this parameter has a major influence on 
cost effectiveness and, importantly, recent evidence would appear to support a more 
conservative approach in the modelling of the link between chlamydia and PID [15].  
There are a number of limitations in our study. Firstly, the adopted modeling approach 
is open to criticism. In a study comparing three alternative models, Kretzschmar et al 
[4] provide an overview of the general weaknesses in such models including the 
approach adopted in this analysis. These relate broadly to the technical difficulties 
associated with the modelling of dynamic sexual networks as well as the lack of good 
quality empirical data to parameterise and fit the models.  
More specifically, the model we adopt is the most optimistic of three considered by 
Kretzschmar et al [4] in terms of its impact on prevalence rates. This is attributed in 
part to the relatively low level of pre-screening treatment of chlamydia infection 
assumed in this model compared to the alternatives. Were prevalence rates to remain 
higher screening would appear more cost effective than suggested here.This further 
highlights the importance of the underlying assumptions of the models used to 
evaluate chlamydia screening programmes in determining their cost effectiveness and 
raises the question as to whether adopting an alternative approach would materially 
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alter the results presented. It also points to the need for accurate chlamydia prevalence 
estimates, both in the generally population and in population sub-groups.  
While we would expect the cost of identifying a positive case in the years post 
screening implementation to be reduced if a more pessimistic model was adopted 
(given that there would be more residual cases in the target population), we would not 
expect the resulting impact in terms of overall cost effectiveness to be considerable. 
This conclusion is based on the results from the ‘Pee-in-a-pot’ analysis and the 
Clinical Setting sensitivity analyses which explored screening scenarios with lower 
coverage in the target population (based on lower offer and acceptance rates) than the 
base-case strategy.  
As would be the case with a more pessimistic model, the impact of screening in 
reducing prevalence is less for the lower coverage scenarios than for the base-case 
strategy, resulting in more residual cases in the target population which can be 
detected at a lower cost per case. However, the results for these ‘low coverage’ 
analyses did not fundamentally differ from those of the base-case analysis in that there 
remained substantial uncertainty as regards the likely cost effectiveness of the 
screening strategies. Consequently, we believe our results to be robust to the choice of 
a more pessimistic model than that which was employed.  
Finally, the modeling analysis does not allow for the consideration of additional 
‘spillover’ effects which may arise, specifically in terms of the other sexually 
transmitted infections which would be identified and treated as a result of chlamydia 
screening. Given the complexities of including such effects in the modeling 
framework, these were not examined. 
Secondly, we assume that England and Ireland share similar age-related patterns of 
sexual behaviour so that the dynamic network model deployed was applicable to the 
Irish setting. While there may be real differences that were not accounted for, the 
differences in behaviours are considered to be small and unlikely to have a major 
impact on results. Furthermore, an important difference between the settings is that 
screening in the pilot study was not offered to young persons less than 18 years of age 
due to legal advice received by the study research team.  
The risk of complications may be greater in adolescent females in this age group and a 
pool of infection could be maintained in this cohort, if their sexual networks include 
older men who do not accept screening, which could mean that prevalence reductions 
would be more modest than those modelled. Nonetheless, given the results from the 
English analysis by Adams et al [6] which explicitly include this cohort, it is unlikely 
that their inclusion of in this analysis would fundamentally change the results from a 
cost effectiveness perspective. 
Thirdly, approximately two thirds of the population in Ireland, who do not meet the 
financial eligibility criteria, must pay (per-visit) to access primary care services. 
Eligibility for free services has been shown to have a significant impact on primary 
care attendance rates in Ireland [29]. In the base-case Clinical Setting analysis, we 
adopted combined attendance rate data for eligible and ineligible patient groups from 
a nationally representative study [16]. In doing so, we do not explicitly distinguish the 
results for those individuals who are eligible and those who must pay to access such 
care. Nonetheless, it is important to note that given the nature of the programme those 
in higher socioeconomic groups who are ineligible for free primary care services are 
less likely to be offered screening than those who are eligible, if the latter are more 
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frequent attenders.  If this was the case, it could contribute to a negative effect on 
equity, in the sense that, assuming there is equal need, it would not provide equal 
access to chlamydia screening especially for those just above the income threshold for 
a medical card. 
Finally, economic evaluation in Ireland is complicated by a paucity of resource 
utilisation, unit costs and utility data. In some cases, we adopted UK resource data to 
detail the treatment process of chlamydia complications, as national data were not 
readily available. The assumption that the management of infection matches that in 
the UK was deemed acceptable by expert opinion from within our study group that 
included public health consultants as well as those involved in the treatment of 
chlamydia. Similarly, utility data were estimated based from external data sources. 
Indeed, utility data associated with chlamydia infection and complications is not 
widely available and further research is required to improve the QALY estimates 
adopted in studies such as ours. 
In conclusion, we examined the costs and cost effectiveness of opportunistic 
screening delivered in clinical and non-clinical settings in Ireland. Clinical Setting 
screening is unlikely to be considered cost effective while the cost effectiveness of 
‘Pee-in-a-pot’ screening is dependent on decision makers being willing to pay a 
threshold in the region of €45,000 per QALY gained. This is open to question given 
current economic conditions in Ireland. Finally, all evidence presented is qualified by 
the underlying assumptions of the adopted models, which play an important role in 
evaluating chlamydia screening programmes and in determining their cost 
effectiveness. 
 Table 5. Incremental Cost Effectiveness Results (Screening Versus No Screening) 
Screening Scenario Total Cost (€) MOs QALYs Lost   
No Screening 702,074 1,317 84   
Clinical Screening Programme 4,960,942 618 39   
‘Pee-in-a-pot’ Screening Programme 802,587 1,273 81   
Incremental Analysis 
(Screening minus No Screening) 
Incremental Cost 
(€) 
Incremental 
MOs 
Incremental 
QALYs 
Incremental Cost per 
MOA (€) 
Incremental Cost per 
QALY Gained (€) 
Clinical Screening : Base-Case Analysis 4,258,868 699 45 6,093 94,717 
Pee in the Pot Screening Programme 100,513 44 3 2,294 34,486 
Sensitivity Analysis      
PID Progression Rate = 1% (down from 10%) 4,406,776 191 6 23,107 700,144 
PID Progression Rate = 30% (up from 10%) 3,874,293 1,731 99 2,238 39,126 
Male Acceptance 50% (down from 64%) 4,155,594 688 44 6,037 93,890 
Female Acceptance 64% (down from 85%) 4,177,059 661 42 6,321 98,802 
Male and Female Acceptance 50% 4,029,756 583 37 6,907 108,254 
Male and Female Acceptance 80% 4,318,392 722 46 5,984 92,949 
Partner Notification 40% (up from 20%) 4,560,910 838 54 5,446 84,541 
Offer 5% (down from 70%) 548,702 124 8 4,427 69,991 
Offer 20% (down from 70%) 1,800,512 384 24 4,686 74,045 
Offer 40% (down from 70%) 3,025,369 543 35 5,573 87,132 
Offer 100% (up from 70%) 5,094,959 810 52 6,291 97,733 
No minimum gap between screens 6,760,135 805 52 8,403 129,303 
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GP Only  Led Programme 4,836,584 673 43 7,189 113,523 
Practice Nurse Only Led Programme 2,814,887 699 45 4,027 62,603 
Discount Rate 0% (down from 3.5%) 4,835,806 906 86 5,336 56,020 
Discount Rate 6% (up from 3.5%) 3,690,117 592 30 6,233 124,576 
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5. Summary of Key Findings 
1. While the modelled scenario for chlamydia screening in combined clinical 
settings (general practice, student health and family planning clinics) would 
likely to be an effective strategy for reducing overall prevalence, if adequate 
rates of test offers and uptakes were achieved, it would be expensive in that it 
would require extensive additional healthcare resources. Decision makers 
must determine whether the benefits generated are sufficient to justify the 
additional resources required to implement the intervention in practice. This 
notwithstanding, it appears unlikely that Clinical Setting screening would be 
considered cost effective given current economic circumstances in Ireland. 
2. The modelled scenario for screening offered in the form of a short duration 
mass testing ‘Pee-in-a-pot’ campaign in third level educational/college settings 
may be cost effective if decision makers in Ireland are willing to pay a cost 
effectiveness threshold in the region of €45,000 per additional QALY gained. 
This is open to question given the current economic climate and its resulting 
impact in terms of imposing further constraints on healthcare budgets. It is 
also important to note that this strategy would have minimal in impact in 
reducing overall chlamydia prevalence in the population, if not supported by 
general population screening and prevention strategy. Furthermore, 
consideration must be given to equity concerns arising from offering screening 
in a manner that excludes members of the target population who do not attend 
third level institutions.   
6. Potential limitations of this study 
1. Economic modelling of infectious disease is a highly complex and imperfect 
science. We used a model which represents current best practice with respect 
to the state of the art for the modelling of chlamydia. The technical limitations 
associated with individual based stochastic simulation models, which are 
discussed in detail by Kretzschmar et al [4], are applicable to the current 
analysis. Furthermore the adopted approach is considered optimistic when 
compared to the alternative modelling approaches available. Nonetheless, it is 
unlikely that applying the more conservative models would have generated 
fundamentally different results from those presented. 
2. The economic modelling process was limited in some cases by a lack of 
nationally available data. In such instances, we adopted data from the 
international clinical and economic literature. This approach, whilst 
unavoidable, assumes that epidemiological data, healthcare utilisation data and 
utility/QALY data from external sources are directly transferable to the Irish 
setting.  
3. The process of conducing economic evaluation in Ireland is complicated by 
the lack of a national database of unit cost data for the Irish health care system. 
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7. Recommendations 
A. If a Chlamydia screening programme is recommended: 
 The results from the economic evaluation do not support the widespread 
adoption of opportunistic chlamydia screening in combined clinical settings as 
delivered in the pilot study. Alternative models, in which screening is offered 
to a subsection of the target population or to those who are most likely to 
benefit, would need to be identified and evaluated if policy makers wish to 
have a better knowledge-base for decision-making. 
B: Further studies needed 
 Further research is required to identify and evaluate alternative models of 
opportunistic screening which target subsections of the population of interest 
and those who are most likely to benefit. 
 Further evidence is required to address the uncertainties that pervade the 
existing models of chlamydia infection and transmission 
 Further evidence is required on the chlamydia prevalence, QALY impacts and 
healthcare utilisation related to the complications associated with chlamydia 
both in Ireland and internationally 
 A national healthcare unit cost database, along the lines of the reference cost 
databases that are in existence in the UK, is required to facilitate the process of 
economic evaluation and health technology assessment in Ireland.  
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Appendix A. Dynamic Model Methodology 
The dynamic model was parameterised using empirical data from national and 
international data sources.  Where possible, data from the pilot study and other Irish 
data sources were adopted. In other cases, such as with respect to behavioural settings, 
adopted input parameters were based on earlier published work by Adams et al [6] 
and Turner et al [5]. 
Appendix Table 1. Base case input parameter values used in dynamic model 
PARAMETER LIST 
SETUP PARAMETERS 
40 Number of realisations 
20000 Number of men + women (total population = 2N) 
16 45 Start age, end age 
SCREENING PARAMETERS 
0.5 0.8 Proportion attending health care setting in a year (Male, Female), used to calculate number attending 
per day 
1 1 Individual chance attending (M/F) e.g. 1 – everyone may attend, 0.5 half attend, the rest never attend 
0 365 Screen type (0 - continuous, 1 - pulse), screen frequency (if pulse) 
16 29 Start screen age (Male & Female), end screen age (Male & Female) 
0.64 0.85 Screen accept (Male, Female) We used these parameters in combination with probability 
of attending/being offered screening to look at the effects 
of heterogeneity in the coverage of a screening programme 
- see additional notes 
0.7 0.7 Screen offer (Male, Female) 
1 1 Individual accept (Male, Female) 
0.95 0.95 Treatment effectiveness (Male, female) 
1 1 Test sensitivity, specificity  
7 10 Mean refractory period following infection in days, (distribution) 
365  Screen interval 
0.2 0.2 Proportion of partners of men notified, proportion of partners of women notified 
90  Time frame for notifying partners (notify partners from last 3 months) 
7 2 Delay in partner notification following index treatment  mean (distribution) 
180  Definition of recent partner (duration of partnership < x days) 
0.25 1 Frequency of sex acts in long partnerships (per day), frequency of sex acts in short partnerships 
BIOLOGICAL PARAMETERS 
0.0375 Transmission probability (Male to Female and Female to Male) 
30 Average duration of symptomatic infection (Male & Female) 
180 Average duration of asymptomatic infection (Male & Female) 
1825 Maximum duration of infection before spontaneous resolution (5 years) 
0.05 Proportion population initially infected 
0 0.045 Proportion symptomatic infections (Male, female) 
0.1 Proportion progressing to PID from untreated chlamydia infection (F) 
0.02 Proportion progressing to epididymitis from untreated chlamydia infection (M) 
30 
SEXUAL BEHAVIOUR PARAMETERS 
14  Average duration of short partnerships (days)  
900 900 Average duration of long partnerships (Male, female) 
0.6 0.5 Initial proportion preferring short partnerships (Male, female) 
0.04 0.08 Proportion that switch from short to long per year (Male, female) 
200 200 Duration increase in long partnerships per year, Male Female (i.e. partnerships become more stable 
over time) 
14 (2)  Average gap between partnerships  (distribution) 
0.05  Proportion with concurrent partnerships, if under 35 years 
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Appendix Table 2. Risk of developing complications following acute chlamydial 
infection 
Complication Probability  Probability applied 
to: 
Distribution type 
Symptomatic PID 
(women) 
1%,  10%, 30% Asymptomatic 
chlamydia infection 
Scenario analysis 
Ectopic pregnancy 
(women) 
7.6% Symptomatic PID Beta (constrained by 0,1) 
Tubal factor infertility 
(women) 
10.8% Symptomatic PID 
(exclude those with 
EP) 
Beta (constrained by 0,1) 
Neonatal conjunctivitis  14.8% Infected women 
giving birth vaginally  
Beta (constrained by 0,1) 
Neonatal pneumonia 7.0% Infected women 
giving birth vaginally 
Beta (constrained by 0,1) 
Epididymitis (men) 2% Asymptomatic 
chlamydial infection 
Fixed  
(Source: Adams et al [6]) 
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Appendix B. Costing Methodology 
A healthcare system perspective was adopted with respect to costs, with two broad 
components included in the analysis: (i) the cost of screening, and (ii) the costs of 
complications arising from untreated infections.  
Appendix B.1. Screening Programme Costing Methodology 
Clinical Setting Screening Programme 
Base-Case Analysis 
Cost per Offer         €26 
Cost per Negative Case         €66 
Cost per Positive Case       €152 
Partner Notification        €74 
 
GP Led Programme Analysis 
Cost per Offer         €38 
Cost per Negative Case         €91 
Cost per Positive Case       €177 
Partner Notification        €74 
 
Nurse Led Programme Analysis 
Cost per Offer         €15 
Cost per Negative Case         €42 
Cost per Positive Case       €128 
Partner Notification        €74 
 
 
‘Pee-in-a-pot’ Screening Programme 
Cost per Negative Case         €39 
Cost per Positive Case       €125 
Partner Notification        €74 
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A: Clinical Setting Screening Programme 
1. Cost per Offer  
 
Item     Measure Unit   Unit Cost 
 
A. Overhead Costs        €11.21  
 
Personnel (Research Health Advisor)      €6.84 
Telephone         €0.15  
Computer Equipment        €0.65  
Stationary         €0.61  
Printing & Photocopying       €0.62 
Travel          €0.59 
Provider Pack         €1.75  
 
B. Variables Costs 
  
(1) Test Offer         €15.13 
 
% of GP Offers   50  %  
% of PN Offers   50  % 
GP Time    6.68  Minute   €3.97 
PN Time    6.68  Minute   €0.53 
Information Leaflet   1  Per Item  €0.10 
 
 
Estimated Cost per Offer    [A+B(1)]   €26.34 
 
 
Other Screening Models: 
GP Led Programme        €37.83 
Nurse Led Programme       €14.85 
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2. Cost per Negative Case 
 
Item     Measure Unit   Unit Cost 
 
A. Overhead Costs        €11.21  
 
Personnel (Research Health Advisor)      €6.84 
Telephone         €0.15  
Computer Equipment        €0.65  
Stationary         €0.61  
Printing & Photocopying       €0.62 
Travel          €0.59 
Provider Pack         €1.75  
  
B. Variable Costs 
 
(1) Accepting the Test Offer      €16.63 
 
% of GP Offers   50  %  
% of PN Offers   50  % 
GP Time    6.68  Minute   €3.97 
PN Time    6.68  Minute   €0.53 
Information Leaflet   1  Per Person  €0.10 
Request Form    1  Per Person  €0.50 
Sample Container   1  Per Person  €0.50 
Transport bag    1  Per Person  €0.50 
 
(2) Testing and final diagnosis      €38.34  
 
Laboratory testing   1  Per Person  €20.38 
% of GP Notifications  50  %  
% of PN Notifications  50  % 
GP time    7.64  Minute   €3.97 
PN time     8.67  Minute   €0.53 
Phone Call    1  Per Person  €0.50 
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Estimated Cost per Negative Case   [A +B(1) + B(2)]   €66.18 
 
 
Other Screening Models: 
 
GP Led Programme        €90.54 
Nurse Led Programme       €41.83 
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3.  Cost per Positive Case 
 
Item     Measure Unit   Unit Cost 
 
A. Overhead Costs        €11.21  
 
Personnel (Research Health Advisor)      €6.84 
Telephone         €0.15  
Computer Equipment        €0.65  
Stationary         €0.61  
Printing & Photocopying       €0.62 
Travel          €0.59 
Provider Pack         €1.75  
 
B. Variable Costs 
 
(1) Accepting the Test Offer      €16.63 
 
% of GP Offers   50  %  
% of PN Offers   50  % 
GP Time    6.68  Minute   €3.97 
PN Time    6.68  Minute   €0.53 
Information Leaflet   1  Per Person  €0.10 
Request Form    1  Per Person  €0.50 
Sample Container   1  Per Person  €0.50 
Transport bag    1  Per Person  €0.50 
 
(2) Testing and final diagnosis      €38.34  
 
Laboratory testing   1  Per Person  €20.38 
% of GP Notifications  50  %  
% of PN Notifications  50  % 
GP time    7.64  Minute   €3.97 
PN time     8.67  Minute   €0.53 
Phone Call    1  Per Person  €0.50 
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(3) Treatment         €69.78 
 
% of consultations by GP  100  %  
GP time     14.71  Minute   €3.97 
Receptionist time   2.5  Minute   €0.21 
Information Leaflet   1  Per Person  €0.10 
Consent Form    1  Per Person  €0.10 
PN Form    1  Per Person  €0.10 
% treated with Azithromycin  97  % 
% treated with Doxycycline  3  % 
Azithromycin    1  Per Dose  €10.70 
Doxycycline    1  Per Dose  €5.77 
 
(4)  Retesting         €16.15 
 
% of Individuals retested  60  % 
PN/HA time    7.6  Minute   €0.53 
Phone Call    2  Per Person  €0.50 
Sample Container   1  Per Person  €0.50 
Transport Bag    1  Per Person  €0.50 
Request Form    1  Per Person  €0.50 
Laboratory testing   1  Per Person  €20.38 
 
 
 
Estimated Cost per Positive Case  [A +B(1) + B(2) + B(3) + B(4)]  €152.10 
 
 
Other Screening Models: 
 
GP Led Programme        €176.46 
Nurse Led Programme       €127.75 
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B: ‘Pee-in-a-pot’ Screening  
1. Cost per Negative Case 
 
Item     Measure Unit   Unit Cost 
 
A. Overhead Costs        €12.10 
 
Personnel (Research Health Advisor)      €6.84 
Telephone         €0.15  
Computer Equipment        €0.65  
Stationary         €0.61  
Printing & Photocopying       €0.62 
Travel          €0.59 
Consumables, Materials, Volunteer Payments    €2.64  
  
B. Variable Costs 
 
(1) Test         €1.60 
 
Information Leaflet   1  Per Person  €0.10 
Urine Container   1  Per Person  €0.50 
Transport bag    1  Per Person  €0.50 
Request Form    1  Per Person  €0.50 
 
 
(2) Testing and final diagnosis      €25.48  
 
Laboratory testing   1  Per Person  €20.38 
PN time     8.67  Minute   €0.53 
Phone Call    1  Per Person  €0.50 
 
 
 
Estimated Cost per Negative Case  [A+B(1)+B(2)]   €39.18 
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2. Cost per Positive Case 
 
Item     Measure Unit   Unit Cost 
 
A. Overhead Costs        €12.10 
 
Personnel (Research Health Advisor)      €6.84 
Telephone         €0.15  
Computer Equipment        €0.65  
Stationary         €0.61  
Printing & Photocopying       €0.62 
Travel          €0.59 
Consumables, Materials, Volunteer Payments    €2.64  
  
B. Variable Costs  
  
(1) Accepting the Test Offer      €1.60 
 
Information Leaflet   1  Per Person  €0.10 
Urine Container   1  Per Person  €0.50 
Transport bag    1  Per Person  €0.50 
Request Form    1  Per Person  €0.50 
 
(2) Testing and final diagnosis      €25.48 
 
Laboratory testing   1  Per Person  €20.38 
% of PN Notifications  100  % 
PN time     8.67  Minute   €0.53 
Phone Call    1  Per Person  €0.50 
 
(3) Treatment         €69.78 
 
% of consultations by GP  100  %  
GP time     14.71  Minute   €3.97 
Receptionist time   2.5  Minute   €0.21 
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Information Leaflet   1  Per Person  €0.10 
Consent Form    1  Per Person  €0.10 
PN Form    1  Per Person  €0.10 
% treated with Azithromycin  97  % 
% treated with Doxycycline  3  % 
Azithromycin    1  Per Dose  €10.70 
Doxycycline    1  Per Dose  €5.77 
 
(4) Retesting         €16.15 
 
% of Individuals retested  60  % 
PN/HA time    7.6  Minute   €0.53 
Phone Call    2  Per Person  €0.50 
Sample Container   1  Per Person  €0.50 
Transport Bag    1  Per Person  €0.50 
Request Form    1  Per Person  €0.50 
Laboratory testing   1  Per Person  €20.38 
 
Estimated Cost per Positive Case  [A +B (1) + B(2) + B(3) + B(4)]  €125.10 
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C: Partner Notification & Treatment 
 
A. Contacting Partners       €1.97 
            
% of Partners contacted by Patient 89  % 
% of Partners contacted by PN/HA 11  % 
Nurse/Research Heath Advisor Time 11.67  Minute   €0.53 
Phone Calls    1  Per Person  €0.50 
Contact Cards    1  Per Person  €0.79 
 
B. Partner Treatment       €67.94 
            
% of Partners Treated   65  % 
 
% of Primary Care   69  %  
% of GUM Consultations  31  % 
GP time     14.5  Minute   €3.97 
GUM Clinic Visit   1  Per Visit  €173 
Receptionist time    2.5  Minute   €0.21 
Information Leaflet   1  Per Person  €0.10 
% treated with Azithromycin  97  % 
% treated with Doxycycline  3  % 
Azithromycin    1  Per Dose  €10.70 
Doxycycline    1  Per Dose  €5.77 
 
C.  Partner Testing        3.84  
        
% of Treated Partners Tested  20  % 
 
Sample Container   1  Per Person  €0.50 
Transport Bag    1  Per Person  €0.50 
Request Form    1  Per Person  €0.50 
Laboratory testing 1  Per Person  €20.38 
 
Cost of Partner Notification, Treatment and Testing    
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A. Cost of Notification     Per Person  €1.97 
B. Cost of Treatment     Per Person  €104.53 
C. Cost of Testing     Per Person  €21.28 
Total       [A+B+C]  €128.38 
 
65 % of Partners Treated    
20 % of Treated Partners Tested   
 
Estimated Cost of PNTT  [A+(0.65*B)+(0.65*0.20*C)] €73.75 
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Appendix B.2. Cost Analysis: Screening Unit Cost Data 
Appendix Table 3. Unit costs of materials, consumables, drugs and tests 
Item Baseline (SD) 
€ 2008 
Source 
Sample container 0.50 (0.2) Pilot Study Accounts 
Transport bag 0.50 (0.2) Pilot Study Accounts 
Request form 0.50 (0.2) Pilot Study Accounts 
Information leaflets 0.10 (0.04) Pilot Study Accounts 
Contact cards 0.79 (0.32) Pilot Study Accounts 
Consent form 0.10 (0.04) Pilot Study Accounts 
Partner notification form 0.10 (0.04) Pilot Study Accounts 
Phone call 0.50 (0.2) Eircom 
Azithromycin 10.70 (4.28) MIMS Ireland 
Doxycycline 5.77 (2.31) MIMS Ireland 
Laboratory testing 20.38 (8.15) Laboratory, DOHC 
Pregnancy test 14.00 (5.60) Pilot Study Accounts 
SD - standard deviation. All cost items assumed to be normally distributed  
Appendix Table 4. Unit costs of personnel input  
Item Baseline (SD) 
€ 2008 
Source 
General Practitioner, per minute 3.97 (1.59) Office of Revenue 
Commissioner Report 
Practice Nurse, per minute 0.53 (0.21) Irish Nurses 
Organisation 
GUM Clinic Visit 173.00 (69.20) Case-mix, DOHC 
Receptionist, per minute 0.21 (0.08) IrishJobs.ie 
SD - standard deviation. All cost items assumed to be normally distributed  
Appendix Table 5. Screening process time input 
Screening step  Minutes (SD)  Source 
Practice Nurse time (test offer) 6.68 (2.9) Pilot Study 
General Practitioner time (test offer) 6.68 (2.9) Pilot Study 
Practice Nurse time (notification) 8.67 (3.3) Pilot Study 
General Practitioner time (notification) 7.64 (5.1) Pilot Study 
General Practitioner time (treatment) 14.71 (4.7) Pilot Study 
Receptionist time (treatment) 2.5 (1.7) Pilot Study 
Practice Nurse/HA time (retesting) 7.6 (4.9) Pilot Study 
Practice Nurse/HA time (contacting partners) 11.67 (2.9) Pilot Study 
General Practitioner time (partner treatment) 14.5 (4.7) Pilot Study 
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Receptionist time (partner treatment) 2.5 (1.7) Pilot Study 
SD – standard deviation. All cost items assumed to be normally distributed 
Appendix Table 6. Screening Overheads  
Resource Item Total Cost 
(€) 
Set Up/ 
Running Ratio 
Unit Cost 
per Offer 
(€) 
Source 
Telephone Charges 572.00 0.50 0.15 Pilot Study 
Accounts 
Computer Equipment 1,284.70 1.00 0.65 Pilot Study 
Accounts 
Stationary 2,414.62 0.50 0.61 Pilot Study 
Accounts 
Printing and Photocopying 2,431.00 0.50 0.62 Pilot Study 
Accounts 
Travel Expenses 2,326.45 0.50 0.59 Pilot Study 
Accounts 
Clinical Setting: Provider Pack  1,150.00 1.00 1.75 Pilot Study 
Accounts 
‘Pee-in-a-pot’ Setting: Consumables, 
Materials, Volunteer Payments 
3,459.16 1.00 2.64 Pilot Study 
Accounts 
Programme Administrator (6 month 
screening period) 
26,886.86 0.50 6.84 Pilot Study 
Accounts 
 Cost per offer = (total cost) x (set up/ running ratio) / total screening offers  
Total overhead costs were allocated on the basis of the ratio of time/costs dedicated to the set up versus 
the running of the screening programmes. A cost per offer was allocated based on the total number of 
screening offers in the pilot study.  
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Appendix B.3. Complications of Chlamydia Infection Costing 
Methodology   
The data used to estimate the average cost per complication are presented in the 
following tables. 
Appendix Table 7. Unit costs in the estimation of the costs of infections and 
complications  
Condition Baseline cost 
(SD) 
Source 
Symptomatically infected & actively seeking treatment (women/men) 
GP clinic visit 48.39 (4.36) Irish Office of Revenue 
Commissioner  
GUM clinic visit 173 (69.20) Irish Office of Revenue 
Commissioner  
Diagnosis 92.83 (37.13) Pilot Study Estimate based on 
treatment protocol from Adams at 
al [6] and Irish Unit Costs 
Treatment 10.55 (2.44) Monthly Index of Medical 
Specialities (MIMS) - Ireland  
Pelvic inflammatory disease 
Diagnosis 53.34 (21.33) Pilot Study Estimate based on 
treatment protocol from Adams at 
al [6] and Irish Unit Costs 
Treatment 42.49 (fixed) MIMS Ireland 
Hospital inpatient episode 2,683.89 Weighted average based on bed 
days of diagnoses below 
Other Uterine & Adnexa Procedures for Non-
Malignancy 
4,048.68 
(1,619.47) 
Case-mix, DOHC 
Endoscopic and Laparoscopic Procedures for 
Female Reproductive System 
2,936.40 
(1,174.56) 
Case-mix, DOHC 
Infections, Female Reproductive System  2,134.51 (853.80) Case-mix, DOHC 
Hospital outpatient episode  173 (69.20) Case-mix, DOHC 
Epididymitis 
Diagnosis 92.83 (37.13) Pilot Study Estimate based on 
treatment protocol from Adams at 
al [6] and Irish Unit Costs 
Treatment  5.77 (fixed) MIMS Ireland 
Hospital inpatient episode 2,410.32 Weighted average based on bed 
days of diagnoses below 
Testes Procedures W/O CC      3,008.44 
(1,203.38) 
Case-mix, DOHC 
Inflammation of the Male Reproductive System W 
CC          
4,632.36 
(1,852.94) 
Case-mix, DOHC 
Inflammation of the Male Reproductive System 
W/O CC       
2,087.90 (835.16) Case-mix, DOHC 
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Ectopic pregnancy (all hospital inpatient episodes) 
Ectopic Pregnancy    5,086.80 
(2,034.72) 
Case-mix, DOHC 
Antenatal & Other Obstetric Admission        1,543.41 (617.36) Case-mix, DOHC 
Antenatal & Other Obstetric Admission, Same day               463.98 (185.59) Case-mix, DOHC 
Tubal factor infertility 
Other Uterine & Adnexa Procedures for Non-
Malignancy 
11,369.35 
(4,535.22) 
Case-mix, DOHC 
Neonatal conjunctivitis & pneumonia 
Diagnosis 20.38 (8.15) Pilot Study Estimate based on 
treatment protocol from Adams at 
al [6] and Irish Unit Costs 
Treatment 19.27 (7.71) MIMS Ireland 
Pneumonia hospital inpatient episode 4,379.18 
(1,751.67) 
Case-mix, DOHC 
GP-general practice, GUM-genitourinary medicine; All costs items assumed to be normally distributed, 
truncated at 0, and rounded to the nearest £ for presentation; SD - standard deviation. 
Appendix Table 8.Probability of attending health care settings due to infection 
and complications 
Condition Baseline probability 
(SD) 
Distribution* Source 
Symptomatically infected & actively seeking treatment 
GUM vs. GP clinic Women: 45% (3%), 
Men: 77% (2%) 
Beta Adams et al [6] 
Pelvic inflammatory disease 
Inpatient hospital admission  6.5% (1%) Beta Adams et al [6] 
Outpatient hospital treatment 6.5% (1%) Beta Adams et al [6] 
Epididymitis 
GP vs. GUM clinic 50% (20%) Normal Adams et al [6] 
Inpatient hospital admission 10% (3%) Normal Adams et al [6] 
Tubal factor infertility 
Diagnosis & treatment 50% (20%) Normal Adams et al [6] 
Neonatal pneumonia 
Inpatient hospital admission 19% (8%) Beta Adams et al [6] 
GP-general practice, GUM-genitourinary medicine; *All distributions for probabilities were truncated 
at 0 and 1; SD - standard deviation. 
Note: Data adopted from Adams et al [6] given lack of evidence for the Irish Healthcare Setting. 
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Appendix C. QALY Methodology 
The QALY losses from chlamydia complications were estimated by multiplying the 
duration in a condition by the valuation for each health state: 
Total QALY loss for each state = (1 - quality of life weight) * duration in each state 
Estimates of the quality of life weights (health utility index, HUI) were taken from the 
studies by the Institute of Medicine (2000). Smith et al (2008) have more recently 
published estimates using the time trade off method (TTO) and the visual analogue 
scale (VAS). The Institute of Medicine (2000) values were based on the consensus of 
an expert advisory panel, the TTO/VAS were estimated from sampling women who 
had reported no history of diagnosis with PID or related conditions. The duration of 
each condition was based on Adams et al (2007). Tubal factor infertility was assumed 
to last longer than a year; therefore QALY loss from this condition was discounted in 
future years. In probabilistic analysis, for the Institute of Medicine (2000) estimates, 
the uncertainty around them was unknown and a coefficient of 0.4 was used to 
estimate the SD. For the TTO/VAS estimates, the distribution was assumed to be 
normal with a reported SD as per the publication.  
Appendix Table 9. Quality of life/utility weights, duration status, and estimated 
QALY loss from chlamydia complication states 
State Quality/Utility 
weight* 
Duration 
(years)** 
QALY 
Loss 
Women    
Pelvic inflammatory disease (PID): overall 0.90 0.077 0.008 
     PID - outpatient^ 0.69, 0.87 0.27 0.006 
     PID - inpatient^ 0.60, 0.84 0.005 0.001 
Ectopic pregnancy (EP): overall 0.63, 0.87 0.038 0.010 
Tubal factor infertility 0.66, 0.84 3.468 0.871 
Men    
Epididymitis – overall   0.011 
     Epididymitis - outpatient^ 0.46 0.019 0.010 
     Epididymitis - inpatient^ 0.30 0.003 0.002 
Neonatal    
Neonatal conjunctivitis 0.97 0.042 0.001 
Neonatal pneumonia –overall   0.037 
     Neonatal pneumonia - outpatient^ 0.79 0.167 0.035 
     Neonatal pneumonia - inpatient^ 0.55 0.022 0.010 
QALY- quality adjusted life year;  
*QALY weights were obtained from studies by the Institute of Medicine [19] and Smith et al [20]; 
 ^ Inpatient refers to patients admitted to inpatient hospital care; outpatient is all other hospital and 
community care.  
** Duration data taken from Adams et al [6] 
